NDLI: Markers of Treatment Response to Methotrexate in Rheumatoid Arthritis: Where Do We Stand?

Content Provider	PubMed Central
Author	Halilova, Karina I. Brown, Elizabeth E. Morgan, Sarah L. Bridges, S. Louis Hwang, Min-ho Arnett, Donna K. Danila, Maria I.
Copyright Year	2012
Abstract	Methotrexate (MTX) is the most commonly used disease-modifying antirheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA). However, despite its efficacy and affordability, additional DMARDs or biologic agents are often required in order to achieve the recommended goals of low disease activity or remission. Although well tolerated by most, some patients develop important side effects such as cytopenias, gastrointestinal adverse events (stomatitis, nausea), or abnormal liver function tests, which may limit its use and may result in additional health care costs. Given the clinical implications of widespread use of MTX in RA, various studies have evaluated the role of potential biomarkers in predicting treatment effectiveness of MTX. These biomarkers include RBC MTX polyglutamate (PG) levels; genetic variation in genes from relevant biological and metabolic pathways; gene expression profiles; serum proteins. This paper provides an update on the current data regarding biomarkers of treatment response to MTX.
Related Links	http://dx.doi.org/10.1155/2012/978396
Starting Page	978396
File Format	PDF
ISSN	16879260
e-ISSN	16879279
Journal	International Journal of Rheumatology
Volume Number	2012
Language	English
Publisher	Hindawi Publishing Corporation
Publisher Date	2012-01-01
Access Restriction	Open
Rights Holder	Hindawi Publishing Corporation
Subject Keyword	Research in Higher Education
Content Type	Text
Resource Type	Article
Subject	Immunology Rheumatology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Markers of Treatment Response to Methotrexate in Rheumatoid Arthritis: Where Do We Stand?

Gene therapy for arthritis – where do we stand?

Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs?

Gene therapy for arthritis – where do we stand?

Ultrasound and its clinical use in rheumatoid arthritis: where do we stand?

Infections in biological and targeted synthetic drug use in rheumatoid arthritis: where do we stand? A scoping review and meta-analysis

Clinical predictors of response to methotrexate in patients with rheumatoid arthritis: a machine learning approach using clinical trial data

The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now?

Differential DNA methylation correlates with response to methotrexate in rheumatoid arthritis

Markers of Treatment Response to Methotrexate in Rheumatoid Arthritis: Where Do We Stand?

Similar Documents

Markers of Treatment Response to Methotrexate in Rheumatoid Arthritis: Where Do We Stand?

Gene therapy for arthritis – where do we stand?

Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs?

Gene therapy for arthritis – where do we stand?

Ultrasound and its clinical use in rheumatoid arthritis: where do we stand?

Infections in biological and targeted synthetic drug use in rheumatoid arthritis: where do we stand? A scoping review and meta-analysis

Clinical predictors of response to methotrexate in patients with rheumatoid arthritis: a machine learning approach using clinical trial data

The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now?

Differential DNA methylation correlates with response to methotrexate in rheumatoid arthritis

Markers of Treatment Response to Methotrexate in Rheumatoid Arthritis: Where Do We Stand?